A stability-indicating reversed phase high performance liquid chromatographic method was developed to quantify axitinib (AXT) in pharmaceutical dosage form. Chromatographic separation was achieved on a C-18 (250× 4.6 mm i.d., 5μm) column using 0.1% OPA: acetonitrile (55:45, v/v) as mobile phase at a flow rate of 1 mL.min -1 with a column temperature of 30°C and PDA detection at 210 nm. Establishment of calibration curve revealed linearity in the range of 12.5-75.0 μg.mL -1 along with values of accuracy and precision within the acceptance limit of mean percent recoveries between 98.7-100.3%. Limit of detection and limit of quantitation were found to be 0.06 and 0.17μg.mL -1 . Analysis of system suitability revealed high degree of method reproducibility and robustness. The developed method showed high specificity for AXT and its degradation products formed during forced degradation conditions. The developed method also demonstrated suitability for routine analysis of AXT in bulk drug and pharmaceutical dosage forms.
Introduction
Axitinib (AXT), N-methyl-2-[[3-[(1E)-2-(2-pyridinyl) ethenyl]-1H-indazol-6-yl]thio]benzamide, is indicated for second-line treatment for metastatic clear cell renal cell carcinoma (Rothermundt et. al. 2016) . The structure of AXT is shown in Fig. 1 .
AXT is a novel anti renal carcinoma drug which has only two reported analytical methods for its quantification in pharmaceutical dosage forms and biological samples including HPLC (Reddy et. al. 2012 ) and LC-MS (Lu et. al. 2016) . But the newer drug candidates such as AXT should have a superior analytical method such as stability-indicating HPLC method for effectively separating the possible degradation products produced from the drug and quantitatively measure the actual amount of AXT present in a drug product. However, the reported chromatographic method for estimation of AXT possess multiple drawbacks like non stability-indicating nature, low sensitivity, complex mobile phase mixture, strict monitoring of pH etc. Moreover, there was no reported literature available describing the degradation products of AXT and their detection employing a suitable analytical technique. This calls for development of a simple, fast, sensitive, efficient and reliable stability indicating liquid chromatographic method for quantification of AXT in bulk drug and pharmaceutical formulation. The method was also validated as per requirements of ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005) guideline. 
Experimental

Materials
HPLC grade acetonitrile, analytical grade sodium hydroxide, hydrochloric acid and hydrogen peroxide were procured from Rankem, India. The water for HPLC was obtained from Rankem, India. AXT (purity > 99.7%) was obtained as gift sample from Pfizer, India. Purity of the standard drug was confirmed by testing the melting point. Tablet formulation containing 5 mg of AXT was procured from the local market and analysed by HPLC.
Instrumentation and Chromatographic Conditions
Quantitative HPLC was performed on a Waters HPLC 2965 equipped with auto-injector and a Waters PDA 2996 detector. Signal was recorded and integrated using Empower 2 Software. An ultrasonicator was used for preparation of mobile phase and drug solutions. A pH meter (Thermo Scientific) was used for measurement of pH of aqueous phase.
Chromatography was performed on a Kromasil C-18, (250 × 4.6 mm i.d., 5 µm particle size) column at 30°C temperature. The mobile phase was 0.1% OPA: acetonitrile (55:45, v/v) at a flow rate of 1mL.min -1 in isocratic mode. Both the acetonitrile and aqueous phase were ultrasonicated up to 20 min for degassing before use.PDA detection was carried out at 210nm. The injection volume was 10µL. The run time was 6min for all the solutions except the forced degradation samples where run time was extended up to 10 min to find out presence of any possible degradation products.
Preparation of Standard Stock Solutions and Calibration Curve
Standard stock solution was prepared by transferring 5mg of drug to 10mL volumetric flask .The drug was then dissolved in 7mL of diluents (acetonitrile: water, 50:50,v/v), shaken well and finally volume was made up to get a concentration of 500µg.mL -1 . The standard drug solution was filtered through a 0.2µm membrane filter. The stock solution was stored at 2-8°C.
For preparation of calibration curve, suitable aliquots of the working stock solution were taken at concentrations of 12.5,25, 37.5, 50, 62.5 and 75 µg.mL -1 for AXT and finally diluted with diluent. A volume of 10µL was auto injected in duplicate, from each standard solution and chromatograms were recorded. Calibration curve was plotted taking concentration (µg.mL -1 ) on x-axis and average peak areas on y-axis. The calibration curve data was further subjected to regression analysis to find out the regression statistics. ANOVA was performed to check the appropriateness of linearity data.
Analysis of Pharmaceutical Dosage Form
Five tablets were weighed accurately and finely powdered. A quantity of tablet powder equivalent to 5mg of AXT was transferred into a 10mL volumetric flask congaing 5mL of diluent. Ultrasonication was performed for 30 minutes and volume was made up with the diluent, followed by filtration through 0.22µm membrane filter. The tablet solution was further diluted with the diluent to obtain test solutions within the linearity range. The filtered solution was further properly diluted for analysis, to get a test concentration of 50µg.mL -1 . All the solutions were stored at 2-8°C temperature up to 3days for future use. The test solutions were injected and chromatograms were obtained. The amount of AXT present in the test solution was calculated using the calibration curve.
Forced Degradation Study
Specificity of the method was determined by checking interference of any of the possible degradation products produced during forced degradation study of AXT. PDA detection was applied to find out the purity angle and purity threshold of degraded samples. Forced degradation of the drug was done with 2N HCl, 2N NaOH, 20% v/v H2O2, thermal (105°C) and photolysis (200 Watt hours/m 2 ) for discovering the stability nature of the drug. After the fixed time period the stressed samples were analysed. For every stress condition a solution of concentration 50 µg.mL -1 of AXT was prepared. The specific stress conditions are described as follows.
Acidic degradation: Acidic degradation was carried out by adding 1 mL of 2N HCl to the drug solution aliquot, and after 30 min of reflux at 60°C neutralizing the mixture by adding 2N NaOH.
Alkaline degradation: Alkaline degradation was carried out by adding 1 mL of 2N NaOH to the drug solution aliquot, and after 30 min of reflux at 60°C neutralizing the mixture by adding 2N HCl.
Oxidative degradation: Oxidative degradation was performed by exposing the drug solution aliquot to 1 mL of 20% (v/v) H2O2 with 30 min of reflux at 60°C.
Thermal degradation: Thermal degradation was performed by heating the drug solution at 105°C for 6h on a thermostatically controlled water bath.
Photolytic degradation: Photolytic degradation was carried out by exposing the drug solution to UV light (200 Watt hours.m 2 -1 ) inside a photostability chamber for 7days.
Accuracy and Precision
To check the accuracy of the proposed method, recovery studies were carried out at 50,100 and 150 % of the test concentration as per ICH guidelines. The recovery study was performed three times at each level.
The precision (intraday and interday) of the method was ascertained from the peak areas obtained by determination of six separately prepared replicates of fixed concentration of AXT (50µg.mL -1 ).System precision was also determined by hexaplicate injection of fixed concentration of AXT (50µg.mL -1 ). The percent relative standard deviations were calculated.
Robustness
Robustness of the method was studied by deliberately changing the mobile phase flow rate (±0.1mL.min -1 ), mobile phase composition (±2%) and column temperature (±2°C).The effect was studied in terms of various system suitability parameters like retention time, plate number and tailing factor. Solution stability study was also carried out by keeping the sample solutions at 25±2° C for 24hrs.
System Suitability
The System Suitability was calculated for different parameters like retention time, plate number, tailing factor, LOD and LOQ. The LOD and LOQ were separately determined based on the Signal to Noise ratio. For LOD the S/N ratio is 3:1.For LOQ the S/N ratio is 10:1.
Results and Discussion
HPLC Method Development and Optimization
HPLC method development needs adequate knowledge on the diverse aspects of chromatographic instrumentation with detailed understanding of the analytes physical and chemical properties. The different chromatographic parameter includes mobile phase composition, pH of aqueous phase, type of stationary phase, mobile phase flow rate etc. Selection of a suitable buffer according to the analytes pKa value significantly affects the retention of a compound. The selected candidate AXT is reported to exhibit pKa value of 4.8, thus it was assumed, employing a mobile phase with pH around its pKa value (±2 pH units) can produce better chromatographic performance. Hence, 0.1% OPA solution pH maintained at 2.8 (low pH) was selected to obtain best selectivity for AXT. A C-18 column was used for separation of the compound as it was found suitable for the analyte. Different Fig. 2 (A) and (B) , respectively. The current method is found superior to the reported LC method for quantification of AXT in solid oral dosage forms (Table 1) .
Method Validation
AXT has linearity over concentrations ranging from 12.5 to 75.0µg.mL -1 . The slope (a) and intercept (b) were found to be 5111.6 and 14319, respectively. Correlation coefficient (r 2 ) was found to be 0.999. These results indicate a good linear relationship between peak area and the amount of analyte in the range studied. Regression analysis of linearity data showed overall goodness of fit. Satisfactory values were obtained for statistical parameters such as multiple R (0.9999), R 2 (0.9998), adjusted R 2 (0.9997) and standard error (3579.8). ANOVA suggested appropriateness (Pvalue<0.05) of the linearity data.
The % recovery of AXT in tablet dosage form was found to be more than 100.26%. The good % recovery and non-interference in the separation of AXT due to formulation components suggests that; the excipients present in the formulation have no effect in the determination process and the method is selective. The results are given in Table 2 . Recovery by proposed method a ,
%±S.D.;R.S.D,%
Tablet 5 100.26±1.13,1.13 a average of three determinations Specificity of the method was ascertained by checking any interference due to excipients or degradation products produced after forced degradation of AXT. The stress conditions like 2N HCl, 2N NaOH, 20% v/v H2O2, 105°C temperature and UV radiation were applied on AXT. Some well separated non-interfering extra peaks were noticed after the forced degradation of AXT. Hence the method was found to be specific and stability-indicating. AXT was found stable in all the applied stress conditions with less than 5% degradation (Table 3) . Fig. 3 (A) , (B), (C), (D), (E) and (F) represents the chromatograms of acid, alkali, oxidation, thermal, photolysis and neutral hydrolysis degraded AXT, respectively. Table 4 . The RSD for method (intraday and interday) and system precision were found to be less than 2% showing high degree of precision as shown in Table 5 . A critical evaluation of the method was performed. Also the LOD and LOQ values indicate superior sensitivity of the method. The system suitability parameters are shown in Table 6 . Table 6 System Suitability Robustness was assured in accordance with deliberate changes made in mobile phase flow rate (mL.min -1 ), organic phase proportion (%) and column temperature (°C). Various system suitability parameters were evaluated to determine the robustness of the method. The results for system suitability parameters are presented in Table 7 . The result of solution stability was satisfactory with a recovery more than 99 % after 24 hr, indicating no significant loss of the analyte in the selected mobile phase. 
